A unified classification approach rating clinical utility of protein biomarkers across neurologic diseases
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 1,24 MB, PDF-dokument
A major evolution from purely clinical diagnoses to biomarker supported clinical diagnosing has been occurring over the past years in neurology. High-throughput methods, such as next-generation sequencing and mass spectrometry-based proteomics along with improved neuroimaging methods, are accelerating this development. This calls for a consensus framework that is broadly applicable and provides a spot-on overview of the clinical validity of novel biomarkers. We propose a harmonized terminology and a uniform concept that stratifies biomarkers according to clinical context of use and evidence levels, adapted from existing frameworks in oncology with a strong focus on (epi)genetic markers and treatment context. We demonstrate that this framework allows for a consistent assessment of clinical validity across disease entities and that sufficient evidence for many clinical applications of protein biomarkers is lacking. Our framework may help to identify promising biomarker candidates and classify their applications by clinical context, aiming for routine clinical use of (protein) biomarkers in neurology.
Originalsprog | Engelsk |
---|---|
Artikelnummer | 104456 |
Tidsskrift | EBioMedicine |
Vol/bind | 89 |
Antal sider | 13 |
ISSN | 2352-3964 |
DOI | |
Status | Udgivet - 2023 |
Bibliografisk note
Funding Information:
Funding: BMBF (FKZ: FKZ161L0214B , FKZ161L0214C ClinspectM), Munich Cluster for Systems Neurology (EXC 2145 SyNergy—ID 390857198), Deutsche Forschungsgemeinschaft (DFG, German Research Foundation).
Funding Information:
This work was supported by the Bundesministerium für Bildung und Forschung (BMBF) project CLINSPECT-M (FKZ: FKZ161L0214B , FKZ161L0214C ), the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy – ID 390857198). No funding source had any role in the writing of the manuscript or the decision to submit for publication. No authors have been paid to write this Review by a pharmaceutical company or other agency. We thank Johanna Tueshaus for critically revising the manuscript.
Publisher Copyright:
© 2023 The Author(s)
Antal downloads er baseret på statistik fra Google Scholar og www.ku.dk
ID: 337587441